Key Data From EV-103: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer

home / pivotal-practice-views-with-the-oncology-brothers / key-data-from-ev-103-enfortumab-vedotin-plus-pembrolizumab-in-locally-advanced-or-metastatic

The Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Jonathan E. Rosenberg, MD, to discuss recent data from a phase 2 study investigating enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic bladder cancer.